A systematic review of patient reported outcomes in phase II or III clinical trials of myelodysplastic syndromes and acute myeloid leukemia

Myelodysplastic syndromes (MDS) are a heterogeneous group of hematological diseases of ineffective hematopoiesis with a risk for progression to acute myeloid leukemia (AML) [1,2]. More than 80% of individuals with MDS are 65 years old or older at the time of diagnosis [3]; the average age at diagnosis is 67 years old [4]. Anemia and fatigue are common in MDS, and are often managed through red blood cell transfusions. In addition, MDS can transform into AML requiring intensive chemotherapy and prolonged hospital stays of approximately 30 days [5], which can lead to severe toxicities and functional impairments [5 –8].

Source: Leukemia Research - June 7, 2018 Category: Hematology Authors: Ashley Leak Bryant, Sarah W. Drier, Sejin Lee, Antonia V. Bennett Source Type: research